Display Settings:

Format

Send to:

Choose Destination
    Lung Cancer. 2004 Aug;45 Suppl 2:S75-8.

    Value of FDG PET in the management of NSCLC.

    Source

    Medizinische Universitätsklinik, Innere Medizin V, Universitätsklinikum des Saarlandes, D-66421 Homburg, Germany. Dieter.Ukena@Klinikum-Bremen-Ost.de

    Abstract

    Metabolic imaging with positron emission tomography (PET) using 18F-fluoro-2-deoxy-glucose (FDG) has been accepted as an important imaging modality in lung cancer. FDG PET may have important impacts on the management of lung-cancer patients, for instance by improvement of locoregional (mediastinal) and extrathoracic staging (unexpected metastases). Interesting findings have now been reported in the response assessment to induction therapy providing results of greater prognostic significance than that obtained by conventional imaging methods. In the field of thoracic irradiation, FDG PET may provide advantages in terms of reduced toxicity, treatment intensification, better local tumour control and increased survival.

    PMID:
    15552785
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk